Literature DB >> 19001805

Co-expression of KIT receptor and its ligand stem cell factor in Merkel cell carcinoma.

Konstantin Krasagakis1, Sabine Kruger-Krasagakis, Jürgen Eberle, Aristidis Tsatsakis, Androniki D Tosca, Efstathios N Stathopoulos.   

Abstract

BACKGROUND/AIMS: KIT receptor has been implicated in the pathogenesis of cancer, either by mutation or autocrine activation. Merkel cell carcinoma (MCC) is a rare KIT-positive cutaneous tumor. We investigated the co-expression of KIT and its ligand stem cell factor (SCF) in MCC.
METHODS: Sixteen specimens from 13 MCC patients of various tumor stages were examined by immunohistochemistry for SCF, KIT, Ki67/MIB-1 and cleaved caspase 3 expression, and for apoptosis by TUNEL.
RESULTS: KIT was expressed in 13 of 16 tumors, and SCF in 15 of 16 specimens. Co-expression of KIT and SCF was detected in 12 of 16 tumors. KIT and SCF immunoreactivity scores were independent of tumor stage. Ki67/MIB-1 proliferation rates were high, whereas apoptosis rates were low, and did not depend on KIT or SCF expression.
CONCLUSION: Co-expression of KIT and SCF in a high percentage of MCC tumors hints to an autocrine mechanism. KIT and SCF expression in primary tumors and in metastases suggests an early event in Merkel cell transformation. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001805     DOI: 10.1159/000173704

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  7 in total

1.  Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status.

Authors:  Aleodor A Andea; Raj Patel; Selvarangan Ponnazhagan; Sanjay Kumar; Patricia DeVilliers; Darshana Jhala; Isam E Eltoum; Gene P Siegal
Journal:  Hum Pathol       Date:  2010-07-01       Impact factor: 3.466

2.  BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.

Authors:  Qiang Shao; Aarthi Kannan; Zhenyu Lin; Brendan C Stack; James Y Suen; Ling Gao
Journal:  Cancer Res       Date:  2014-10-02       Impact factor: 12.701

3.  KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells.

Authors:  Shu Yang; Wen-shuai Li; Fang Dong; Hai-mei Sun; Bo Wu; Jun Tan; Wan-jing Zou; De-shan Zhou
Journal:  J Cell Mol Med       Date:  2014-09-12       Impact factor: 5.310

4.  Unremitting cell proliferation in the secretory phase of eutopic endometriosis: involvement of pAkt and pGSK3β.

Authors:  Yanira Franco-Murillo; José Antonio Miranda-Rodríguez; Erika Rendón-Huerta; Luis F Montaño; Gerardo Velázquez Cornejo; Lucila Poblano Gómez; Francisco Javier Valdez-Morales; Ignacio Gonzalez-Sanchez; Marco Cerbón
Journal:  Reprod Sci       Date:  2014-09-06       Impact factor: 3.060

5.  Merkel cell carcinoma: a retrospective study on 48 cases and review of literature.

Authors:  Fernando Cirillo; Marco Vismarra; Ines Cafaro; Mario Martinotti
Journal:  J Oncol       Date:  2012-09-13       Impact factor: 4.375

6.  Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?

Authors:  Guilherme Rabinowits
Journal:  Cancers (Basel)       Date:  2014-05-16       Impact factor: 6.639

7.  A Proteomic Study of Human Merkel Cell Carcinoma.

Authors:  Qiang Shao; Stephanie D Byrum; Linley E Moreland; Samuel G Mackintosh; Aarthi Kannan; Zhenyu Lin; Michael Morgan; Brendan C Stack; Lynn A Cornelius; Alan J Tackett; Ling Gao
Journal:  J Proteomics Bioinform       Date:  2013-11-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.